• BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

    ソース: Nasdaq GlobeNewswire / 15 9 2016 05:38:09   America/Los_Angeles

    N/A
シェアする